Successful Large Gene Augmentation of USH2A with Non-viral Episomal Vectors

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2023 Jun 20

PMID 37337429

Authors

Maria Toms

Lyes Toualbi

Patrick V Almeida

Richard Harbottle

Mariya Moosajee

Affiliations

Soon will be listed here.

Abstract

USH2A mutations are a common cause of autosomal recessive retinitis pigmentosa (RP) and Usher syndrome, for which there are currently no approved treatments. Gene augmentation is a valuable therapeutic strategy for treating many inherited retinal diseases; however, conventional adeno-associated virus (AAV) gene therapy cannot accommodate cDNAs exceeding 4.7 kb, such as the 15.6-kb-long USH2A coding sequence. In the present study, we adopted an alternative strategy to successfully generate scaffold/matrix attachment region (S/MAR) DNA plasmid vectors containing the full-length human USH2A coding sequence, a GFP reporter gene, and a ubiquitous promoter (CMV or CAG), reaching a size of approximately 23 kb. We assessed the vectors in transfected HEK293 cells and USH2A patient-derived dermal fibroblasts in addition to ush2a zebrafish microinjected with the vector at the one-cell stage. pS/MAR-USH2A vectors drove persistent transgene expression in patient fibroblasts with restoration of usherin. Twelve months of GFP expression was detected in the photoreceptor cells, with rescue of Usher 2 complex localization in the photoreceptors of ush2a zebrafish retinas injected with pS/MAR-USH2A. To our knowledge, this is the first reported vector that can be used to express full-length usherin with functional rescue. S/MAR DNA vectors have shown promise as a novel non-viral retinal gene therapy, warranting further translational development.

Citing Articles

Frontier applications of retinal nanomedicine: progress, challenges and perspectives.

Tang Z, Ye F, Ni N, Fan X, Lu L, Gu P J Nanobiotechnology. 2025; 23(1):143.

PMID: 40001147 PMC: 11863789. DOI: 10.1186/s12951-025-03095-6.

Key challenges in developing a gene therapy for Usher syndrome: machine-assisted scoping review.

Bhat R, Nallamothu B, Shethia F, Chhaya V, Khambholja K J Community Genet. 2024; 15(6):735-747.

PMID: 39549230 PMC: 11645336. DOI: 10.1007/s12687-024-00749-0.

Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing.

Liu Z, Chen S, Davis A, Lo C, Wang Q, Li T Adv Sci (Weinh). 2024; 11(42):e2405628.

PMID: 39297417 PMC: 11558111. DOI: 10.1002/advs.202405628.

Accelerated discovery and miniaturization of novel single-stranded cytidine deaminases.

Deng J, Li X, Yu H, Yang L, Wang Z, Yi W Nucleic Acids Res. 2024; 52(18):11188-11202.

PMID: 39271120 PMC: 11472066. DOI: 10.1093/nar/gkae800.

Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress.

Liu Y, Zong X, Cao W, Zhang W, Zhang N, Yang N Biomolecules. 2024; 14(8).

PMID: 39199291 PMC: 11352491. DOI: 10.3390/biom14080903.

References

Rivolta C, Sweklo E, Berson E, Dryja T . Missense mutation in the USH2A gene: association with recessive retinitis pigmentosa without hearing loss. Am J Hum Genet. 2000; 66(6):1975-8. PMC: 1378039. DOI: 10.1086/302926. View

Maerker T, van Wijk E, Overlack N, Kersten F, McGee J, Goldmann T . A novel Usher protein network at the periciliary reloading point between molecular transport machineries in vertebrate photoreceptor cells. Hum Mol Genet. 2007; 17(1):71-86. DOI: 10.1093/hmg/ddm285. View

Jenke A, Scinteie M, Stehle I, Lipps H . Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation. Mol Biol Rep. 2004; 31(2):85-90. DOI: 10.1023/b:mole.0000031363.35839.46. View

van Wijk E, Pennings R, Te Brinke H, Claassen A, Yntema H, Hoefsloot L . Identification of 51 novel exons of the Usher syndrome type 2A (USH2A) gene that encode multiple conserved functional domains and that are mutated in patients with Usher syndrome type II. Am J Hum Genet. 2004; 74(4):738-44. PMC: 1181950. DOI: 10.1086/383096. View

Bozza M, Green E, Espinet E, De Roia A, Klein C, Vogel V . Novel Non-integrating DNA Nano-S/MAR Vectors Restore Gene Function in Isogenic Patient-Derived Pancreatic Tumor Models. Mol Ther Methods Clin Dev. 2020; 17:957-968. PMC: 7218229. DOI: 10.1016/j.omtm.2020.04.017. View

Eudy J, Weston M, Yao S, Hoover D, Rehm H, Ma-Edmonds M . Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science. 1998; 280(5370):1753-7. DOI: 10.1126/science.280.5370.1753. View

Dona M, Slijkerman R, Lerner K, Broekman S, Wegner J, Howat T . Usherin defects lead to early-onset retinal dysfunction in zebrafish. Exp Eye Res. 2018; 173:148-159. PMC: 6054812. DOI: 10.1016/j.exer.2018.05.015. View

Samanta A, Stingl K, Kohl S, Ries J, Linnert J, Nagel-Wolfrum K . Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations. Int J Mol Sci. 2019; 20(24). PMC: 6940777. DOI: 10.3390/ijms20246274. View

Tian M, Wang W, Delimont D, Cheung L, Zallocchi M, Cosgrove D . Photoreceptors in whirler mice show defective transducin translocation and are susceptible to short-term light/dark changes-induced degeneration. Exp Eye Res. 2013; 118:145-53. PMC: 4408763. DOI: 10.1016/j.exer.2013.10.021. View

10.

Colella P, Trapani I, Cesi G, Sommella A, Manfredi A, Puppo A . Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther. 2014; 21(4):450-6. DOI: 10.1038/gt.2014.8. View

11.

Dulla K, Slijkerman R, van Diepen H, Albert S, Dona M, Beumer W . Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021; 29(8):2441-2455. PMC: 8353187. DOI: 10.1016/j.ymthe.2021.04.024. View

12.

Adato A, Lefevre G, Delprat B, Michel V, Michalski N, Chardenoux S . Usherin, the defective protein in Usher syndrome type IIA, is likely to be a component of interstereocilia ankle links in the inner ear sensory cells. Hum Mol Genet. 2005; 14(24):3921-32. DOI: 10.1093/hmg/ddi416. View

13.

Bucher K, Rodriguez-Bocanegra E, Dauletbekov D, Fischer M . Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety. Prog Retin Eye Res. 2020; 83:100915. DOI: 10.1016/j.preteyeres.2020.100915. View

14.

Maddalena A, Tornabene P, Tiberi P, Minopoli R, Manfredi A, Mutarelli M . Triple Vectors Expand AAV Transfer Capacity in the Retina. Mol Ther. 2018; 26(2):524-541. PMC: 5835116. DOI: 10.1016/j.ymthe.2017.11.019. View

15.

Sun D, Sun W, Gao S, Wei C, Naderi A, Schilb A . Formulation and efficacy of ECO/pRHO-ABCA4-SV40 nanoparticles for nonviral gene therapy of Stargardt disease in a mouse model. J Control Release. 2020; 330:329-340. PMC: 9066847. DOI: 10.1016/j.jconrel.2020.12.010. View

16.

Fink T, Klepcyk P, Oette S, Gedeon C, Hyatt S, Kowalczyk T . Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther. 2006; 13(13):1048-51. DOI: 10.1038/sj.gt.3302761. View

17.

Kusuluri D, Guler B, Knapp B, Horn N, Boldt K, Ueffing M . Adhesion G protein-coupled receptor VLGR1/ADGRV1 regulates cell spreading and migration by mechanosensing at focal adhesions. iScience. 2021; 24(4):102283. PMC: 8024656. DOI: 10.1016/j.isci.2021.102283. View

18.

Yu D, Zou J, Chen Q, Zhu T, Sui R, Yang J . Structural modeling, mutation analysis, and expression of usherin, a major protein in inherited retinal degeneration and hearing loss. Comput Struct Biotechnol J. 2020; 18:1363-1382. PMC: 7317166. DOI: 10.1016/j.csbj.2020.05.025. View

19.

Liu X, Bulgakov O, Darrow K, Pawlyk B, Adamian M, Liberman M . Usherin is required for maintenance of retinal photoreceptors and normal development of cochlear hair cells. Proc Natl Acad Sci U S A. 2007; 104(11):4413-8. PMC: 1838616. DOI: 10.1073/pnas.0610950104. View

20.

Tornabene P, Trapani I, Minopoli R, Centrulo M, Lupo M, de Simone S . Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci Transl Med. 2019; 11(492). PMC: 6863751. DOI: 10.1126/scitranslmed.aav4523. View